Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Candel TherapeuticsCADL +4.81%25 EV-to-EBIT is -11.52 as of Jul. 27, 2026. GuruFocus rates CADL with a GF Score™ of 25/100. The stock has 3 warning signs investors should review. Among 378 Biotechnology companies, Candel Therapeutics ranks worse than 264550% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Candel Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $213.40 Mil.
Candel Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Candel Therapeutics EV-to-EBIT Related Terms
Candel Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Candel Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Candel Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Candel Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Candel Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Candel Therapeutics's EV-to-EBIT falls into.
Candel Therapeutics's current Enterprise Value is $588.24 Mil.
Candel Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Candel Therapeutics (CADL) has a EV-to-EBIT of -11.52 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Candel Therapeutics and its competitors. According to the industry distribution chart, Candel Therapeutics ranks #999999 out of 378 companies in the Biotechnology industry.
Is Candel Therapeutics' EV-to-EBIT too high?
Candel Therapeutics' current EV-to-EBIT is -11.52. Based on the distribution chart, Candel Therapeutics ranks #999999 out of 378 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Candel Therapeutics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Candel Therapeutics' EV-to-EBIT compare to NGNE and CTMX?
According to the Biotechnology industry distribution chart, Candel Therapeutics ranks #999999 out of 378 companies for EV-to-EBIT. This places Candel Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 12.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.78, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Candel Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Candel Therapeutics's current EV-to-EBIT is -11.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Candel Therapeutics stock overvalued right now?
Candel Therapeutics (CADL) has a current EV-to-EBIT of -11.52. The current EV-to-EBIT is -11.52. Candel Therapeutics' overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Candel Therapeutics (CADL), the current EV-to-EBIT is -11.52 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
25GF Score
Get the complete analysis for CADL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CADL has been successfully added to your 
